Praxis Precision Medicines Advances Epilepsy Treatment with Promising Study Results and Strong Financial Positioning

Praxis Precision Medicines reported significant advances in its epilepsy treatment initiatives during Q2. The RADIANT study showed vormatrigine achieved a 56.3% reduction in seizures in patients with extensive prior treatments. The POWER1 study is nearing pivotal enrollment, and POWER2 and POWER3 studies are set to commence. The relutrigine program received a breakthrough therapy designation for SCN2A and SCN8A developmental and epileptic encephalopathies. The company remains financially sound to support these developments.

Praxis Precision Medicines Inc. (NASDAQ: PRAX) has made notable strides in its epilepsy treatment initiatives during the second quarter of 2025. The company's RADIANT study, which evaluated the efficacy of vormatrigine in patients with focal epilepsy, reported a 56.3% reduction in seizures. The study enrolled around 50 patients and demonstrated rapid and durable efficacy, with 60% of patients achieving at least a 50% reduction in seizures and approximately 22% becoming seizure-free in the last 28 days of treatment [1].

The company is also advancing its clinical development program for vormatrigine. The POWER1 study, a pivotal Phase 2/3 trial, is nearing enrollment and is expected to finalize in the fourth quarter of 2025. Additionally, Praxis plans to initiate the POWER2 study in the third quarter of 2025, which will enroll approximately 400 patients to evaluate vormatrigine as a single agent for 12 weeks. The company is also planning the POWER3 study, which will evaluate vormatrigine in patients with refractory epilepsy currently on 1-2 anti-seizure medications (ASMs), expected to commence in the first half of 2026 [2].

Moreover, the relutrigine program has received a breakthrough therapy designation for SCN2A and SCN8A developmental and epileptic encephalopathies. This designation recognizes the potential of relutrigine to provide a significant improvement in the treatment of these conditions. Praxis has a robust pipeline with several other programs advancing toward key milestones, including the EMBOLD study for relutrigine and the ESSENTIAL3 studies for ulixacaltamide [2].

Praxis remains financially sound to support these developments, with a cash runway extending into 2028. The company's shares jumped 4.83% in premarket trading to $56.70 following the presentation of the RADIANT study results, reflecting investor optimism about the company's broader pipeline potential [2].

References:
[1] https://www.clinicaltrialsarena.com/news/praxis-vormatrigine-eliminates-seizures-in-22-of-patients-in-phase-ii-trial/
[2] https://www.investing.com/news/company-news/praxis-precision-q3-2025-slides-radiant-study-reveals-promising-epilepsy-results-93CH-4167891